Latest news
AXSM Stock Advances on CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030 - TradingViewTradingView · Mon, 10 Aug 2026 18:51:23 GMTAXSM: Q2 revenue rose 46% to $218M, driven by AUVELITY's new indication and robust portfolio growth - TradingViewTradingView · Mon, 10 Aug 2026 13:51:33 GMTAXSM: Q2 revenue rose 46% year-over-year, driven by AUVELITY's growth and new Alzheimer's indication - TradingViewTradingView · Mon, 10 Aug 2026 13:21:06 GMTAxsome Therapeutics Q2 Earnings Call Highlights - TradingViewTradingView · Mon, 10 Aug 2026 13:03:42 GMTAXSM: Revenue up 46% YoY to $218.4M, driven by AUVELITY and SUNOSI growth; strong pipeline progress - TradingViewTradingView · Mon, 10 Aug 2026 11:11:49 GMTAXSM Q2'26 Earnings: EPS estimate is (0.89) USD - TradingViewTradingView · Fri, 07 Aug 2026 11:00:05 GMT